Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cost-effectiveness of strategies to increase screening coverage for cervical cancer in Spain, the CRIVERVA study

  • Trapero Bertrán, Marta
  • Acera Pérez, Amelia
  • De Sanjose, Silvia|||0000-0002-5909-676X
  • Manresa, J. M|||0000-0001-8306-5798
  • Rodríguez Capriles, Diego
  • Rodríguez Martínez, Ana
  • Bonet Simó, Josep Maria|||0000-0002-7981-5880
  • Sánchez Sánchez, Norman
  • Hidalgo Valls, Pablo
  • Díaz Sanchís, Mireia
The aim of the study is to carry out a cost-effectiveness analysis of three different interventions to promote the uptake of screening for cervical cancer in general practice in the county of Valles Occidental, Barcelona, Spain. Women aged from 30 to 70 years (n = 15,965) were asked to attend a general practice to be screened. They were randomly allocated to one of four groups: no intervention group (NIG); one group where women received an invitation letter to participate in the screening (IG1); one group where women received an invitation letter and informative leaflet (IG2); and one group where women received an invitation letter, an informative leaflet and a phone call reminder (IG3). Clinical effectiveness was measured as the percentage increase in screening coverage. A cost-effectiveness analysis was performed from the perspective of the public health system with a time horizon of three to five years - the duration of the randomised controlled clinical trial. In addition, a deterministic sensitivity analysis was performed. Results are presented according to different age groups. The incremental cost-effectiveness ratio (ICER) for the most cost-effective intervention, IG1, compared with opportunistic screening was € 2.78 per 1% increase in the screening coverage. The age interval with the worst results in terms of efficiency was women aged < 40 years. In a population like Catalonia, with around 2 million women aged 30 to 70 years and assuming that 40% of these women were not attending general practice to be screened for cervical cancer, the implementation of an intervention to increase screening coverage which consists of sending a letter would cost on average less than € 490 for every 1000 women. ClinicalTrials.gov Identifier: . The online version of this article (doi:10.1186/s12889-017-4115-0) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Increasing Cervical Cancer Screening Coverage: A randomised, Community-Based Clinical Trial

  • Acera Pérez, Amelia
  • Manresa, J.M.|||0000-0001-8306-5798
  • Rodríguez Capriles, Diego
  • Rodríguez Martínez, Ana
  • Bonet Simó, Josep Maria|||0000-0002-7981-5880
  • Trapero Bertrán, Marta
  • Hidalgo Valls, Pablo Andres
  • Sánchez Sánchez, Norman
  • De Sanjose, Silvia|||0000-0002-5909-676X
Background. Opportunistic cervical cancer screening can lead to suboptimal screening coverage. Coverage could be increased after a personalised invitation to the target population. We present a community randomized intervention study with three strategies aiming to increase screening coverage.Methods. The CRICERVA study is a community-based clinical trial to improve coverage of population based screening in the Cerdanyola SAP area in Barcelona.A total of 32,858 women residing in the study area, aged 30 to 70 years were evaluated. A total of 15,965 women were identified as having no registration of a cervical cytology in the last 3.5 years within the Public Health data base system. Eligible women were assigned to one of four community randomized intervention groups (IGs): (1) (IG1 N = 4197) personalised invitation letter, (2) (IG2 N., Conclusions. The study confirms that using individual contact methods and assigning a fixed screening date notably increases participation in screening. The response to the invitation is strongly dependent on age.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Probability estimation of a Carrington-like geomagnetic storm

  • Moriña, David|||0000-0001-5949-7443
  • Serra Mochales, Isabel|||0000-0002-2465-8574
  • Puig, Pedro|||0000-0002-6607-9642
  • Corral, Álvaro|||0000-0002-5280-2692
Intense geomagnetic storms can cause severe damage to electrical systems and communications. This work proposes a counting process with Weibull inter-occurrence times in order to estimate the probability of extreme geomagnetic events. It is found that the scale parameter of the inter-occurrence time distribution grows exponentially with the absolute value of the intensity threshold defining the storm, whereas the shape parameter keeps rather constant. The model is able to forecast the probability of occurrence of an event for a given intensity threshold; in particular, the probability of occurrence on the next decade of an extreme event of a magnitude comparable or larger than the well-known Carrington event of 1859 is explored, and estimated to be between 0.46% and 1.88% (with a 95% confidence), a much lower value than those reported in the existing literature.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Online Cost-Effectiveness ANalysis (OCEAN), a user-friendly interface to conduct cost-effectiveness analyses for cervical cancer

  • Moriña, David|||0000-0001-5949-7443
  • Martí, José Ignacio
  • Puig, Pedro|||0000-0002-6607-9642
  • Díaz Sanchís, Mireia
Most cost-effectiveness analyses in the context of cervical cancer prevention involve the use of mathematical models to simulate HPV infection, cervical disease and prevention strategies. However, it is common for professionals who would need to perform these analyses to not be familiar with the models. This work introduces the Online Cost-Effectiveness ANalysis tool, featuring an easy-to-use web interface providing health professionals, researchers and decision makers involved in cervical cancer prevention programmes with a useful instrument to conduct complex cost-effectiveness analyses, which are becoming an essential tool as an approach for supporting decision-making that involves important trade-offs. The users can run cost-effectiveness evaluations of cervical cancer prevention strategies without deep knowledge of the underlying mathematical model or any programming language, obtaining the most relevant costs and health outcomes in a user-friendly format. The results provided by the tool are consistent with the existing literature. Having such a tool will be an asset to the cervical cancer prevention community, providing researchers with an easy-to-use instrument to conduct cost-effectiveness analyses.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer, results from the EPIC Cohort

  • Roura, Esther
  • Travier, Noémie
  • Waterboer, Tim
  • De Sanjose, Silvia|||0000-0002-5909-676X
  • Bosch José, Francesc Xavier|||0000-0002-7172-3412
  • Pawlita, Michael
  • Pala, Valeria
  • Weiderpass, Elisabete
  • Margall, Núria|||0000-0001-9370-6931
  • Dillner, Joakim
  • Gram, Inger T.
  • Tjønneland, Anne
  • Munk, Christian
  • Palli, Domenico
  • Khaw, Kay-Tee
  • Overvad, Kim
  • Clavel-Chapelon, Françoise
  • Mesrine, Sylvie
  • Fournier, Agnès
  • Fortner, Renée T.
  • Ose, Jennifer
  • Steffen, Annika
  • Trichopoulou, Antonia
  • Lagiou, Pagona
  • Orfanos, Philippos
  • Masala, Giovanna
  • Tumino, Rosario
  • Sacerdote, Carlotta
  • Polidoro, Silvia
  • Mattiello, Amalia
  • Lund, Eiliv
  • Peeters, Petra H.
  • Bueno-de-Mesquita, H. Bas
  • Quirós García, José Ramón
  • Sánchez Pérez, María José|||0000-0003-4817-0757
  • Navarro Sánchez, Carmen|||0000-0001-8896-7483
  • Barricarte, Aurelio
  • Larrañaga, Nerea
  • Ekström, Johanna
  • Lindquist, David
  • Idahl, Annika
  • Travis, Ruth C.
  • Merritt, Melissa A.
  • Gunter, Marc J.
  • Rinaldi, Sabina
  • Tommasino, Massimo
  • Franceschi, Silvia
  • Riboli, Elio
  • Castellsagué, Xavier|||0000-0002-0802-3595
In addition to HPV, high parity and hormonal contraceptives have been associated with cervical cancer (CC). However, most of the evidence comes from retrospective case-control studies. The aim of this study is to prospectively evaluate associations between hormonal factors and risk of developing cervical intraepithelial neoplasia grade 3 (CIN3)/carcinoma in situ (CIS) and invasive cervical cancer (ICC). We followed a cohort of 308,036 women recruited in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study. At enrollment, participants completed a questionnaire and provided serum. After a 9-year median follow-up, 261 ICC and 804 CIN3/CIS cases were reported. In a nested case-control study, the sera from 609 cases and 1,218 matched controls were tested for L1 antibodies against HPV types 11,16,18,31,33,35,45,52,58, and antibodies against Chlamydia trachomatis and Human herpesvirus 2. Multivariate analyses were performed to estimate hazard ratios (HR), odds ratios (OR) and corresponding 95% confidence intervals (CI). The cohort analysis showed that number of full-term pregnancies was positively associated with CIN3/CIS risk (p-trend = 0.03). Duration of oral contraceptives use was associated with a significantly increased risk of both CIN3/CIS and ICC (HR = 1.6 and HR = 1.8 respectively for ≥15 years versus never use). Ever use of menopausal hormone therapy was associated with a reduced risk of ICC (HR = 0.5, 95%CI: 0.4-0.8). A non-significant reduced risk of ICC with ever use of intrauterine devices (IUD) was found in the nested case-control analysis (OR = 0.6). Analyses restricted to all cases and HPV seropositive controls yielded similar results, revealing a significant inverse association with IUD for combined CIN3/CIS and ICC (OR = 0.7). Even though HPV is the necessary cause of CC, our results suggest that several hormonal factors are risk factors for cervical carcinogenesis. Adherence to current cervical cancer screening guidelines should minimize the increased risk of CC associated with these hormonal risk factors.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Consumption of ultra-processed food and drinks and chronic lymphocytic leukemia in the mcc-spain study

  • Solans, Marta|||0000-0002-2397-0435
  • Fernández-Barrés, Sílvia|||0000-0002-9977-2291
  • Romaguera, Dora|||0000-0002-5762-8558
  • Benavente, Yolanda|||0000-0003-1422-4614
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Gracia-Lavedan, Esther
  • Costas, Laura
  • Robles, Claudia
  • González Barca, Eva|||0000-0002-1323-1508
  • Banda, Esmeralda de la
  • Alonso, Esther
  • Aymerich, Marta
  • Campo, Elias|||0000-0001-9850-9793
  • Llorca, Javier|||0000-0001-8569-861X
  • Fernández-Tardon, Guillermo|||0000-0002-7680-158X
  • Olmedo-Requena, Rocío|||0000-0003-0054-6700
  • Gimeno, Eva|||0000-0002-3534-6189
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Aragonés, Nuria
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Sanjose, Sílvia de
  • Amiano, Pilar
  • Casabonne, Delphine
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in Western countries. Its etiology is largely unknown but increasing incidence rates observed worldwide suggest that lifestyle and environmental factors such as diet might play a role in the development of CLL. Hence, we hypothesized that the consumption of ultra-processed food and drinks (UPF) might be associated with CLL. Data from a Spanish population-based case-control study (MCC-Spain study) including 230 CLL cases (recruited within three years of diagnosis) and 1634 population-based controls were used. The usual diet during the previous year was collected through a validated food frequency questionnaire and food and drink consumption was categorized using the NOVA classification scheme. Logistic regression models adjusted for potential confounders were used. Overall, no association was reported between the consumption of UPF and CLL cases (OR per each 10% increase of the relative contribution of UPF to total dietary intake = 1.09 (95% CI: 0.94; 1.25)), independently of the Rai stage at diagnosis. However, when analyses were restricted to cases diagnosed within <1 year (incident), each 10% increment in the consumption of UPF was associated with a 22% higher odds ratio of CLL (95% CI: 1.02, 1.47) suggesting that the overall results might be affected by the inclusion of prevalent cases, who might have changed their dietary habits after cancer diagnosis. Given the low number of cases in the subgroup analyses and multiple tests performed, chance findings cannot totally be ruled out. Nonetheless, positive associations found in CLL incident cases merit further research, ideally in well-powered studies with a prospective design.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The use of HPV16-E5, EGFR, and PEGFR as prognostic biomarkers for oropharyngeal cancer patients

  • Taberna, Miren|||0000-0002-2446-186X
  • Torres Tarrés, Montserrat
  • Alejo, María
  • Mena, Marisa|||0000-0003-2163-892X
  • Tous, Sara|||0000-0002-5423-7092
  • Marquez, Sandra
  • Pavón, Miquel A.
  • León, Xavier|||0000-0002-8393-2721
  • Garcia Lorenzo, J.|||0000-0002-6123-7808
  • Guix, Marta|||0000-0002-2143-0697
  • Hijano, Rafael|||0000-0001-6787-5440
  • Bonfill Abella, Teresa|||0000-0003-2775-0293
  • Aguilà, Antón
  • Lozano, Alicia|||0000-0003-0528-5212
  • Mesia, Ricard|||0000-0002-3785-3563
  • Alemany, Laia|||0000-0003-0945-6015
  • Bravo, Ignacio G.
Anti-epidermal-growth-factor-receptor (EGFR) therapies in combination with radiotherapy are being studied on deescalation clinical trials for HPV-related oropharyngeal cancer (OPC) patients. The HPV16-E5 oncoprotein increases recycling of activated EGFR to the cell surface, enhancing factor signal transduction. Our aim was to evaluate viral HPV16-E5 oncogene expression as well as EGFR and phosphorylated-EGFR (pEGFR), protein levels as biomarkers for clinical outcome in a retrospective cohort of OPC patients. Formalin-fixed-paraffin-embedded OPCs were collected from 1990 to 2013. OPC samples containing HPV-DNA were subject to viral E6*I mRNA detection and p16INK4a immunohistochemistry (IHC). HPV16-positive cases were evaluated for HPV16-E5 (RT-PCR) and EGFR/pEGFR (IHC). A stratified and matched random sample of HPV-negative samples was used as control and evaluated for EGFR/pEGFR. Overall survival (OS) and disease free survival (DFS) estimates were assessed for locally advanced OPC patients (stage III, IVa,b 7th edition). Among 788 OPC patient samples, 53 were double positive for HPV16-DNA/p16. HPV16-E5 expression was found in 41 of 53 samples (77.4%). EGFR expression was observed in 37.7 vs 70.8% of HPV16-positive vs HPV-negative samples, respectively; (adjusted OR = 0.15) 5% CI = 0.04-0.56]). Expression of pEGFR followed an inverse pattern with 39.6 and 24.9% detection in HPV16-positive and HPV-negative samples; (adjusted OR = 1.58 [95% CI = 0.48-5.17]). Within HPV16-positive cases, no association between HPV16-E5/EGFR nor pEGFR was observed. With a median follow-up of 39.36 months (min = 0.03 - max = 272.07), the combination of HPV status and EGFR or pEGFR expression were predictors of better OS (p < 0.001, for both) and DFS (p < 0.001 for EGFR and p = 0.003 for pEGFR). HPV16-E5 is highly expressed on HPV16-positive OPCs. Interestingly, HPV16-positive cases expressed significantly more pEGFR while HPV-negative cases expressed more EGFR. The combinations of HPV status and EGFR or pEGFR may be useful biomarkers for evaluating prognosis outcome in OPC patients.